IONIS-GCCRRx
| Clinical data | |
|---|---|
| Synonyms | ISIS-426115; ISIS-GCCRRx |
| Drug class | Antiglucocorticoid |
IONIS-GCCRRx, also known as ISIS-426115, is an antiglucocorticoid which is under development by Ionis Pharmaceuticals (formerly Isis Pharmaceuticals) for the treatment of diabetes mellitus type 2.[1][2] It has also been under investigation for the treatment of Cushing's syndrome, but no development has been reported.[1] The drug is an antisense oligonucleotide against the glucocorticoid receptor.[1] As of December 2017, it is in phase II clinical trials for diabetes mellitus type 2.[1]
See also
References
- 1 2 3 4 http://adisinsight.springer.com/drugs/800035183
- ↑ Chikara, Gaurav; Sharma, Pramod Kumar; Dwivedi, Pradeep; Charan, Jaykaran; Ambwani, Sneha; Singh, Surjit (2017). "A Narrative Review of Potential Future Antidiabetic Drugs: Should We Expect More?". Indian Journal of Clinical Biochemistry. doi:10.1007/s12291-017-0668-z. ISSN 0970-1915.
External links
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.